• Maria A C Veiga, Giselle C Medeiros, Suzana S de Aguiar, Anke Bergmann, and ThulerLuiz C SLCS0000-0003-2550-6537Departament of Clinical Research, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil..
• Research Center, Instituto Nacional de Câncer (INCA); Instituto Federal de Educação, Ciência e Tecnologia Rio de Janeiro (IFRJ), Rio de Janeiro, Brazil.
• J Eval Clin Pract. 2024 Oct 1; 30 (7): 128312941283-1294.

ObjectiveTo identify factors associated with delays in beginning adjuvant therapy and prognosis impacts on non-metastatic breast cancer patients.MethodsThis assessment comprised a prospective cohort study concerning breast cancer patients treated at a public oncology centre. A time interval of ≥60 days between surgery and the beginning of the first adjuvant treatment was categorised as a delay. Factors associated with delays were evaluated through logistic regression analysis and the prognosis effects were assessed by a Cox regression analysis.ResultsThe median time interval between surgery and the first adjuvant treatment for the 401 women included in this study was of 57.0 days (37.0-93.0). Independent factors associated with delays comprised not presenting an overexpression of the HER-2 protein, not having undergone neoadjuvant chemotherapy, and having undergone chemotherapy or other therapeutic modalities other than hormone therapy and chemotherapy as the first adjuvant treatment. Delays did not affect recurrence, distant metastasis, or death risks. Factors associated with recurrence and distant metastasis risks comprised a clinical staging ≥2B, having undergone neoadjuvant chemotherapy, presenting the luminal molecular subtype B and triple-negative tumours, and having children. Factors associated with death comprised triple-negative molecular tumours and neoadjuvant chemotherapy.ConclusionDelays in beginning adjuvant treatment did not affect the prognosis of non-metastatic breast cancer patients. Clinical and treatment-related factors, on the other hand, were associated with delays, and recurrence, distant metastasis, and death risks.© 2024 John Wiley & Sons Ltd.

32 keywords...

hide…